Parkman Healthcare Partners LLC lowered its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 196,805 shares of the company's stock after selling 88,489 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Teva Pharmaceutical Industries were worth $4,338,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the business. FMR LLC grew its position in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the last quarter. Duquesne Family Office LLC lifted its stake in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the period. Clal Insurance Enterprises Holdings Ltd raised its position in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $58,243,000. Finally, Marshall Wace LLP raised its position in shares of Teva Pharmaceutical Industries by 87.8% in the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after buying an additional 2,410,420 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Stock Performance
Shares of NYSE TEVA traded up $0.08 during midday trading on Friday, reaching $16.95. 9,758,609 shares of the company were exchanged, compared to its average volume of 9,995,809. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a fifty day simple moving average of $15.35 and a 200 day simple moving average of $17.41. The stock has a market cap of $19.22 billion, a P/E ratio of -11.69, a PEG ratio of 1.44 and a beta of 0.62.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the company earned $0.48 EPS. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. On average, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on TEVA. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus price target of $24.43.
Check Out Our Latest Research Report on TEVA
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
